🔗 Share this article

The Nobel Prize in medical science has been granted for transformative discoveries that clarify how the immune system targets dangerous pathogens while protecting the healthy tissues.

Three esteemed researchers—Japan's Prof. Sakaguchi and US experts Mary Brunkow and Dr. Ramsdell—share this honor.

Their work uncovered specialized "security guards" within the defense system that eliminate malfunctioning defense cells that could harming the body.

The findings are now enabling innovative therapies for autoimmune diseases and malignancies.

The laureates will divide a prize fund valued at 11 million SEK.

Decisive Findings

"Their work has been decisive for understanding how the immune system operates and the reason we don't all suffer from serious self-attack conditions," stated the chair of the award panel.

The trio's research explain a core question: In what way does the defense system defend us from countless infections while keeping our healthy cells unharmed?

The body's protection system employs white blood cells that scan for signs of disease, even pathogens and germs it has never encountered.

These cells utilize sensors—known as recognition units—that are produced by chance in countless variations.

This provides the defense network the capacity to combat a broad range of threats, but the randomness of the mechanism inevitably creates white blood cells that may target the body.

Protectors of the Immune System

Researchers previously understood that a portion of these harmful white blood cells were eliminated in the immune organ—where immune cells develop.

This year's Nobel Prize honors the identification of T-reg cells—described as the immune system's "security guards"—which patrol the body to neutralize other defenders that assault the healthy cells.

It is known that this mechanism malfunctions in autoimmune diseases such as type-1 diabetes, multiple sclerosis, and rheumatoid arthritis.

The Nobel panel added, "The discoveries have laid the foundation for a new field of investigation and accelerated the development of innovative therapies, for instance for cancer and autoimmune diseases."

Regarding malignancies, T-regs prevent the body from fighting the growth, so studies are aimed at reducing their quantity.

In self-attack disorders, experiments are exploring boosting T-reg cells so the body is no longer being harmed. A comparable approach could also be effective in reducing the chances of organ transplant rejection.

Innovative Studies

Prof Sakaguchi, of a Japanese institution, performed experiments on rodents that had their thymus extracted, causing self-attack conditions.

The researcher showed that introducing defense cells from healthy animals could prevent the disease—implying there was a mechanism for preventing defenders from attacking the body.

Mary Brunkow, from the a research center in Seattle, and Dr. Ramsdell, now at Sonoma Biotherapeutics in a California city, were studying an inherited immune disorder in rodents and people that resulted in the discovery of a genetic factor critical for the way regulatory T-cells operate.

"Their groundbreaking research has uncovered how the immune system is kept in check by T-reg cells, stopping it from mistakenly targeting the healthy cells," said a prominent biological science expert.

"The research is a striking illustration of how fundamental physiological research can have broad consequences for human health."